PharmaMar [clinicaltrials_resource:d44d2029ac9ee2e0039d0728cafbfe3b]
collaborator [clinicaltrials_vocabulary:collaborator]
Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma [clinicaltrials:NCT00027508]clinicaltrials:NCT00229203A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma [clinicaltrials:NCT00359294]A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors [clinicaltrials:NCT00404521]clinicaltrials:NCT00780143A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer [clinicaltrials:NCT00780975]Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas [clinicaltrials:NCT00788099]Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors [clinicaltrials:NCT00877474]Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma [clinicaltrials:NCT00884286]Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors [clinicaltrials:NCT00884845]Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy [clinicaltrials:NCT00900562]clinicaltrials:NCT01102426Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis [clinicaltrials:NCT01149681]Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy [clinicaltrials:NCT01222767]Study in Patients With Advanced Soft Tissue Sarcoma (STS) After Failure of Anthracyclines and/or Ifosfamide [clinicaltrials:NCT01299506]Study of PM060184 in Patients With Advanced Solid Tumors [clinicaltrials:NCT01299636]Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome [clinicaltrials:NCT01314599]Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks [clinicaltrials:NCT01405391]A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer [clinicaltrials:NCT01525589]Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors [clinicaltrials:NCT01831089]A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients [clinicaltrials:NCT01951157]Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors [clinicaltrials:NCT01970540]Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors [clinicaltrials:NCT01970553]Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors [clinicaltrials:NCT01980667]Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma [clinicaltrials:NCT02100657]Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC). [clinicaltrials:NCT02210364]Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients [clinicaltrials:NCT02421588]Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors [clinicaltrials:NCT02451007]Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors [clinicaltrials:NCT02454972]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma [clinicaltrials:NCT00027508]clinicaltrials:NCT00229203A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma [clinicaltrials:NCT00359294]A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors [clinicaltrials:NCT00404521]clinicaltrials:NCT00780143A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer [clinicaltrials:NCT00780975]Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas [clinicaltrials:NCT00788099]Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors [clinicaltrials:NCT00877474]Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma [clinicaltrials:NCT00884286]Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors [clinicaltrials:NCT00884845]Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy [clinicaltrials:NCT00900562]clinicaltrials:NCT01102426Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis [clinicaltrials:NCT01149681]Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy [clinicaltrials:NCT01222767]Study in Patients With Advanced Soft Tissue Sarcoma (STS) After Failure of Anthracyclines and/or Ifosfamide [clinicaltrials:NCT01299506]Study of PM060184 in Patients With Advanced Solid Tumors [clinicaltrials:NCT01299636]Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome [clinicaltrials:NCT01314599]Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks [clinicaltrials:NCT01405391]A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer [clinicaltrials:NCT01525589]Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors [clinicaltrials:NCT01831089]A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients [clinicaltrials:NCT01951157]Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors [clinicaltrials:NCT01970540]Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors [clinicaltrials:NCT01970553]Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors [clinicaltrials:NCT01980667]Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma [clinicaltrials:NCT02100657]Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC). [clinicaltrials:NCT02210364]Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients [clinicaltrials:NCT02421588]Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors [clinicaltrials:NCT02451007]Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors [clinicaltrials:NCT02454972]
source [clinicaltrials_vocabulary:source]
PharmaMar [clinicaltrials_resource:d44d2029ac9ee2e0039d0728cafbfe3b]
Bio2RDF identifier
d44d2029ac9ee2e0039d0728cafbfe3b
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:d44d2029ac9ee2e0039d0728cafbfe3b
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:d44d2029ac9ee2e0039d0728cafbfe3b
title
PharmaMar
@en
type
label
PharmaMar [clinicaltrials_resource:d44d2029ac9ee2e0039d0728cafbfe3b]
@en